Physician profile
Robert B Rosequist
NPI 1699771071
$5,724.19
in general payments reported to CMS, 2019-2025
30 companies · $64.95 in 2025
The $64.95 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $852 · 2021: $2,921 · 2022: $706 · 2023: $485 · 2024: $203 · 2025: $64.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $753.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $1,170.00 | 2021 | |
| Lilly USA, LLC | $640.18 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $575.14 | 2021-2024 | Ubrelvy, Synthroid, Vraylar |
| Novo Nordisk INC | $550.04 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $536.10 | 2019-2024 | Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.45 | 2019-2022 | |
| Amarin Pharma, INC. | $216.12 | 2020-2021 | |
| Pfizer INC. | $208.10 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $204.62 | 2020-2022 | |
| Glaxosmithkline, LLC. | $199.43 | 2020-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.16 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $175.31 | 2019-2023 | Gardasil 9, Vaxneuvance |
| Eisai INC. | $149.79 | 2020-2021 | |
| Amgen INC. | $115.51 | 2021-2024 | Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $105.07 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $82.10 | 2022 | |
| Allergan, INC. | $64.65 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $52.09 | 2019-2021 | |
| Hologic Sales and Service, LLC | $50.98 | 2023-2024 | Thinprep 2000 Processor, Aptima |
| Abbott Laboratories | $33.49 | 2022-2023 | Freestyle Libre 2 |
| Cvrx, INC. | $27.20 | 2025 | Barostim Neo System |
| Ultragenyx Pharmaceutical INC. | $23.24 | 2022 | |
| Paratek Pharmaceuticals, INC. | $20.73 | 2020 | |
| Exact Sciences Corporation | $20.48 | 2024 | Cologuard Collection Kit |
| Dexcom, INC. | $19.92 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.83 | 2019 | |
| Phadia US INC. | $15.99 | 2021 | |
| Lucid Diagnostics INC. | $15.87 | 2023 | |
| Nabriva Therapeutics, Plc | $15.49 | 2021 | |
| Ibsa Pharma INC. | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rosequist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.